Description: Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Home Page: www.shuttlepharma.com
SHPH Technical Analysis
401 Professional Drive
Gaithersburg,
MD
20879
United States
Phone:
(240) 403-4212
Officers
| Name | Title |
|---|---|
| Dr. Anatoly Dritschilo M.D. | Co-Founder, CEO & Chairman of the Board |
| Mr. Peter Dale Dritschilo M.B.A., M.D. | President & COO |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder & Director |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer & Chief Medical Officer |
| Dr. Mira Jung Ph.D. | Co-Founder & Chief Scientific Officer for Biology |
| Mr. Gene Jung Esq. | General Counsel |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1571 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-08-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |